Cytovation is a clinical stage biotech developing CyPep-1, the first synthetic peptide engineered to selectively target tumor cell membranes based on their altered molecular composition. CyPep-1 lyses the cell membranes, exposes antigenic material from within the cancer cells, and induces a tumor-specific immune response. The described mode of action is effective across cancer types and highly synergistic with checkpoint inhibitors. CyPep-1 has entered clinical development in Q1 2019.
Location: Norway, Bergen
Member count: 1-10
Total raised: $28M
Founded date: 2014
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 02.06.2023 | Series A | $8M | - | finsmes.co... |
| 25.01.2022 | Series A | $20M | - | finsmes.co... |
Mentions in press and media 6
| Date | Title | Description | Category | Author | Source |
| 02.06.2023 | Cytovation... | - | - | - | globenewsw... |
| 02.06.2023 | Cytovation... | Cytovation, a Bergen, Norway-b... | Norway | - | finsmes.co... |
| 25.01.2022 | Cytovation... | Cytovation AS, a Bergen, Norwa... | Norway | - | finsmes.co... |
| 25.01.2022 | Norwegian ... | Bergen, Norway-based Cytovatio... | biotech f... | Vishal Sin... | siliconcan... |
| 29.06.2017 | Cytovation... | Cytovation AS, a Bergen, Norwa... | Norway | - | finsmes.co... |
| - | Cytovation | “The power of immunotherapy ca... | - | - | fastfounde... |